Brief: Societal Cdmo Selected By Longboard Pharmaceuticals To Provide Cdmo Services To Support Clinical Development Of Lp352
05/04/2023 12:32
April 5 (Reuters) - Longboard Pharmaceuticals Inc
LBPH.O :
* SOCIETAL CDMO SELECTED BY LONGBOARD PHARMACEUTICALS TO
PROVIDE
CDMO SERVICES TO SUPPORT CLINICAL DEVELOPMENT OF LP352
Source text for Eikon: ID:nGNXkw012
Further company coverage: LBPH.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Longboard Pharmaceuticals
See all newsBrief: Longboard Pharmaceuticals Initiates Phase 3 DEEp OCEAN Study Evaluating Bexicaserin In Developmental And Epileptic Encephalopathies (DEEs)
Longboard Pharmaceuticals Inc expected to post a loss of 62 cents a share - Earnings Preview
Brief: Longboard Pharmaceuticals Under Agreement H Lundbeck Required To Pay Co Reverse Termination Fee Of $158.9 Mln In Cash
U.S. RESEARCH ROUNDUP- Cadence Design Systems, Equity Bancshares, S&P Global
Deals of the day-Mergers and acquisitions